Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, TScan Therapeutics Inc increased its cash reserves by 10.66%, or 13.33m. Cash Flow from Financing totalled 135.44m or 643.47% of revenues. In addition the company used 61.36m for operations while cash used for investing totalled 60.76m.
Cash flow per share | -0.9988 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.82 |
---|---|
Tangible book value per share | 4.82 |
More ▼
Balance sheet in USDView more
Current ratio | 7.77 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.1193 |
---|---|
Total debt/total capital | 0.1066 |
More ▼